Physician profile
Terrie Spohn
NPI 1629387600
$585.97
in general payments reported to CMS, 2019-2025
11 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $206 · 2022: $51.39 · 2023: $68.36 · 2024: $66.48 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $328.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $135.37 | 2021-2025 | |
| Optinose US, INC. | $95.03 | 2021 | |
| Alexion Pharmaceuticals, INC. | $87.73 | 2022-2023 | Strensiq |
| Otsuka America Pharmaceutical, INC. | $76.21 | 2025 | Rexulti |
| Janssen Scientific Affairs, LLC | $50.90 | 2024 | Xarelto |
| Pfizer INC. | $40.24 | 2025 | |
| Novartis Pharmaceuticals Corporation | $35.40 | 2025 | |
| Janssen Pharmaceuticals, INC | $17.49 | 2025 | Spravato |
| Glaxosmithkline, LLC. | $17.38 | 2022 | |
| Merck Sharp & Dohme LLC | $15.58 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Ultragenyx Pharmaceutical INC. | $14.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrie Spohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.